Summary.-Growth of isogeneic transplants of a spontaneous murine adenocarcinoma, which is virtually devoid of tumour-specific transplantation antigens, is inhibited by i.v. injection of C. parvum 3 days after tumour inoculation, or by mixing a small dose of C. parvum with the tumour inoculum. Moreover, the therapeutic effect of cyclophosphamide, followed by i.v. or i.p. injection of C. parvum 5 days later, on established transplants of the same tumour is greater than that of cyclophosphamide alone. These findings are consistent with the hypothesis that in both situations (i.e. before the appearance of a palpable tumour and after reduction of an established tumour transplant with cyclophosphamide) the effect of C. parvum is largely due to activation of macrophages or macrophage precursors. They have the important practical implication that adjuvant therapy with C. parvum may be of value, even with tumours which are devoid of TSTA.
TUMOURS which arise spontaneously in mice of strains with a low tumour incidence often appear to be devoid, or almost devoid, of tumour-specific transplantation antigens (TSTA).
It has been suggested by Hewitt, Blake and Walder (1976) that such tumours provide the only appropriate models for human cancer, on the grounds that human tumours are spontaneous. This proposition seems altogether too extreme since, as discussed at greater length elsewhere (Woodruff, 1977a, b) the distinction between spontaneous and induced tumours is an operational one, and does not necessarily reflect important biological differences. If, as is becoming apparent, accidental exposure to environmental carcinogenic agents of various kinds plays an aetiological role in many tumours, why should these tumours differ fundamentally from tumours deliberately induced with similar agents in laboratory animals? Conversely, why should tumours arising without any obvious environmental cause in highly inbred strains of animals with a low incidence of cancer necessarily be a good model, let alone the only model, for tumours arising in human populations, which are extremely heterogeneous in respect of both their genetic constitution and the environment in which they live? We would however agree with Hewitt et al. (1976) that spontaneous animal tumours merit more extensive study than they have hitherto received, and would ourselves regard them as important models for investigating the possible existence of what might perhaps be termed paraimmunological surveillance mechanisms, i.e. mechanisms which depend on recognition of neoplastic cells by markers other than classical surface antigenic determinants, and the response of tumours to therapeutic procedures which might conceivably augment such mechanisms if, indeed, they do exist.
The development of a spontaneous tumour in a mouse of our breeding colony has provided an opportunity to initiate an investigation of this kind. The present paper is concerned with the origin of the tumour, tests of immunogenicity, and its response in normal mice to treatment with C. parvum, which when administered systemically causes widespread activation of macrophages, and inhibits the growth of many tumours, not only in normal mice but also in thymectomized (Woodruff, Dunbar and Ghaffar, 1973) and congenitally athymic mice (Woodruff and Warner, 1977) . Further experiments, including studies of the growth of the tumour in athymic mice and its response to various therapeutic agents other than C. parrurn will be reported later.
MATERIALS AND METHODS
Origin and propagation of tumour. The tumour appeared in the upper pectoral region of an 11-month-old female CBA/Ca mouse which had produced 7 litters in the previous 9 months. The incidence of spontaneous tumours in this strain is extremely low. The mouse was killed when the tumour was about 12 mm in diameter. The histological appearance was that of a moderately well differentiated adenocarcinoma, and was consistent with a mammary origin. A tumourcell suspension was prepared mechanically without pronase and injected into young adult CBA mice. When the first generation transplants were 10-15 mm in diameter, a cell suspension was prepared from one mouse; some of this was used to inoculate 3 other mice, and the remainder was frozen and stored in liquid N2. Further samples were frozen and stored, and material not required for this purpose or for serial transplantation was used in experiments.
Preparation of cell suspensions.-All tumour cell suspensions wNere prepared with pronase as previously described (Woodruff and Boak, 1966 
Test of immunogenicity of tumour
The results of attempts to immunize mice of the strain of origin against the tumour are summarized in Table I It will be seen that a single i.p. injection of Cy in a dosage of 200 mg/kg body wt to mice bearing transplants of tumour W54 which had attained a diameter of 5 or 9 mm caused a marked but temporary reduction in tumour size, following which growth was resumed at much the same rate as before (Fig. 1) ; the net effect was therefore a significant delay in reaching the diameters used as end-points in the statistical analysis (Table IV and Table V , Group 2). The addition of a single i.v. injection of C. parvum 5 days after the Cy potentiated the effect (Fig. 1) and this is reflected in a further significant prolongation of the time required to attain the chosen end-points (Table IV and Table V (Table IV and Table V immunogenic methylcholanthrene-induced murine fibrosarcomas in normal mice is inhibited by i.v. or i.p. injection of C. parvum a few days before or after tumour inoculation, and also by mixing a small dose of C. parvum with the tumour inoculum or injecting it i.t. 3 days after tumour inoculation, but not by s.c. injection of C. parvum at a remote site Dunbar, 1973, 1975; Woodruff, 1975; Woodruff and Whitehead, 1977) . Further analysis has shown that the therapeutic effect of i.v. and i.p. injection of C. parvurn, and of mixing C. parvum with the tumour-cell inoculum, is well maintained in T-cell-deficient mice Woodruff and Warner, 1977) and is consistent with the hypothesis that it is due, to a substantial extent, to activation of macrophages or macrophage precursors (Woodruff, Ghaffar and Whitehead, 1976) , whereas the effect of i.t. injection of C. parvum (except in the special case in which the C. parvum is mixed and injected with the tumour cells) is highly T-cell dependent.
It seemed possible therefore that i.v. or i.p. injection of C. parvum, and mixing C. parvrum with the tumour-cell inoculum, would also inhibit the growth of isogenic transplants of a non-immunogenic tumour, and, according to Hewitt et al. (1976) , tumours "that arise in otherwise normal low-cancer-strain mice which have received no treatment which is calculated or liable to induce cancer" are in general non-immunogenic, and should therefore provide a good model with which to test this hypothesis.
The tumour (W54) used in the present experiments certainly conforms to the Hewitt et al. criterion of spontaneity, and live challenge after pretreatment with irradiated cells has failed to reveal any evidence of immunogenicity. Live challenge after pretreatment with viable cells followed by amputation, or with mitomycin-treated cells, has also revealed no change in the incidence of tumours, but has revealed a modest but apparently significant reduction in tumour growth rate when the cell dose used for challenge was relatively low. It seems reasonable therefore to describe the tumour as virtually non-immunogenic, though it may well be not absolutely devoid of TSTA or indeed of antigens with a rejectioninducing potential in the autochthonous host.
It is, in our view, an open question whether the same qualification needs to be applied to the tumours used by Hewitt et al. (1976) and indeed to other operationally spontaneous tumours commonly described as non-immunogenic. Our evidence suggesting some degree of immunogenicity is based on 2 forms of pretreatment, one of which (injection of mitomycin-treated cells) was not used by Hewitt et al., and the other which (injection of viable cells followed by amputation) was used by them to a very limited extent. In studying the effect of pretreatment with irradiated cells, which in our experiments revealed no evidence of immunogenicity, Hewitt et al. used what might be regarded as a more refined test, in that they compared the TD50 in pretreated and non-pretreated mice; it is noteworthy however that, while the TD50 was never higher in the pretreated mice, it was often lower, and the suggestion that this might be due to immunological enhancement and hence to tumour antigenicity, though dismissed by Hewitt et al., cannot be excluded on the evidence available. Even if this is not the case, failure to immunize with irradiated cells alone cannot be accepted as conclusive evidence that a tumour is completely non-immunogenic, since, as McKhann (1964) has shown, weak transplantation antigens (associated with the H-1 and H-3 loci in the mouse) may be destroyed by as little as 400 rad irradiation, and it is an open question whether the same is true of weak TSTA.
If we accept that our tumour is virtually non-immunogenic, the present experiments have in the main confirmed our prediction, and have shown that the effects of i.v. injection of C. parvum after tumour inoculation, and of the mixing procedure, are of the same order of magnitude with the immunogenic and non-immunogenic tumours. These results are consistent with the hypothesis that macrophages play a role in surveillance against cancer, and may function in this way even with nonimmunogenic tumours. The findings do not however correspond exactly to those obtained with a highly immunogenic tumour, in that i.v. injection of C. parvum before, and i.p. injection either before or after, tumour inoculation was relatively ineffective with the non-immunogenic tumour. The reason for this difference is the subject of further investigation.
It has also been reported previously that i.p. injection of Cy, followed by i.v. or i.p. injection of C. parvum, was therapeutically more effective against established transplants of a highly immunogenic fibrosarcoma than injection of Cy alone and it has now been shown that the same is true with the non-immunogenic tumour of the present experiments. This suggests that the effect of C. parvum after reduction of the tumour mass with Cy is also due, to a substantial extent, to activation of macrophages, and further experiments have been designed to test this hypothesis.
This last finding is not only of theoretical interest, but has the important practical implication that systemic administration of C. parvum may be of therapeutic value as an adjunct to chemotherapy even in the case of tumours lacking TSTA. It seems likely that this will be true also of other agents, besides C. parvum, which cause widespread activation of macrophages, and it will be of interest to determine whether this form of adjuvant therapy is also effective with non-immunogenic tumours after reduction of the tumour mass by surgical excision or radiotherapy. 
